96 related articles for article (PubMed ID: 26422786)
21. Novel acrylonitrile derived imidazo[4,5-b]pyridines as antioxidants and potent antiproliferative agents for pancreatic adenocarcinoma.
Boček Pavlinac I; Persoons L; Daelemans D; Starčević K; Vianello R; Hranjec M
Int J Biol Macromol; 2024 May; 266(Pt 2):131239. PubMed ID: 38569992
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of matrine contains benzimidazole derivatives as dual TOPOI and PARP inhibitors for cancer therapy.
Qiu G; Xie J; Li F; Han K; Long Q; Kowah JAH; Gao R; Wang L; Liu X
Eur J Med Chem; 2024 Apr; 270():116348. PubMed ID: 38554475
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.
Parchment RE; Doroshow JH
Semin Oncol; 2016 Aug; 43(4):514-25. PubMed ID: 27663483
[TBL] [Abstract][Full Text] [Related]
24. Design of Two New Sulfur Derivatives of Perezone: In Silico Study Simulation Targeting PARP-1 and In Vitro Study Validation Using Cancer Cell Lines.
Rubiales-Martínez A; Martínez J; Mera-Jiménez E; Pérez-Flores J; Téllez-Isaías G; Miranda Ruvalcaba R; Hernández-Rodríguez M; Mancilla Percino T; Macías Pérez ME; Nicolás-Vázquez MI
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255943
[TBL] [Abstract][Full Text] [Related]
25. PAR caps the poles: a specific role for PARP2-inhibition to target the 'clustering' of extra spindle poles in cancer cells.
Wang L; Wulf GM
EBioMedicine; 2024 Jun; 104():105158. PubMed ID: 38749301
[No Abstract] [Full Text] [Related]
26. Discovery of pyrano[2,3-
Abd El-Sattar NEA; Badawy EHK; Elrazaz EZ; Ismail NSM
RSC Adv; 2021 Jan; 11(8):4454-4464. PubMed ID: 35424391
[TBL] [Abstract][Full Text] [Related]
27. Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression.
Teicher BA; Polley E; Kunkel M; Evans D; Silvers T; Delosh R; Laudeman J; Ogle C; Reinhart R; Selby M; Connelly J; Harris E; Monks A; Morris J
Mol Cancer Ther; 2015 Nov; 14(11):2452-62. PubMed ID: 26351324
[TBL] [Abstract][Full Text] [Related]
28. Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite.
Hu H; Serra C; Zhang W; Scrivo A; Fernández-Carasa I; Consiglio A; Aytes A; Pujana MA; Llebaria A; Antolin AA
Cell Chem Biol; 2024 May; 31(5):973-988.e4. PubMed ID: 38335967
[TBL] [Abstract][Full Text] [Related]
29. Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications.
Torrado C; Plummer R; Yap TA
JCO Precis Oncol; 2024 Jun; 8():e2400204. PubMed ID: 38865670
[TBL] [Abstract][Full Text] [Related]
30. Discovery and Development of Promising Anticancer Agents
Carradori S
Anticancer Agents Med Chem; 2024; 24(4):235. PubMed ID: 38745440
[No Abstract] [Full Text] [Related]
31. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
Passeri D; Camaioni E; Liscio P; Sabbatini P; Ferri M; Carotti A; Giacchè N; Pellicciari R; Gioiello A; Macchiarulo A
ChemMedChem; 2016 Jun; 11(12):1219-26. PubMed ID: 26424664
[TBL] [Abstract][Full Text] [Related]
32. Poly(ADP-ribosyl)ation of FOXP3 Protein Mediated by PARP-1 Protein Regulates the Function of Regulatory T Cells.
Luo X; Nie J; Wang S; Chen Z; Chen W; Li D; Hu H; Li B
J Biol Chem; 2015 Nov; 290(48):28675-82. PubMed ID: 26429911
[TBL] [Abstract][Full Text] [Related]
33. 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs).
Threadgill MD
Curr Med Chem; 2015; 22(33):3807-29. PubMed ID: 26429070
[TBL] [Abstract][Full Text] [Related]
34. Intracellular Mono-ADP-Ribosylation in Signaling and Disease.
Bütepage M; Eckei L; Verheugd P; Lüscher B
Cells; 2015 Sep; 4(4):569-95. PubMed ID: 26426055
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological Potential and Synthetic Approaches of Imidazo[4,5-b]pyridine and Imidazo[4,5-c]pyridine Derivatives.
Krause M; Foks H; Gobis K
Molecules; 2017 Mar; 22(3):. PubMed ID: 28273868
[TBL] [Abstract][Full Text] [Related]
36. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
Molecules; 2019 May; 24(10):. PubMed ID: 31108884
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
[TBL] [Abstract][Full Text] [Related]
39. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
[TBL] [Abstract][Full Text] [Related]
40. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
